Searched for
AJANTA PHARMA COMPANY
Vedanta Aluminium set for largecap upgrade in H2 CY26; power, oil & gas arms may turn smallcapsVedanta Aluminium is likely to be upgraded to the large-cap category in AMFI’s H2 CY26 semi-annual reshuffle, while Vedanta Power, Oil & Ga...- Sunil Singhania-backed Abakkus Flexi Cap Fund increases stake in HDFC Bank, RIL and 29 others in MaySunil Singhania-backed Abakkus Flexi Cap Fund significantly increased its holdings in HDFC Bank and Reliance Industries during May. The fun...
- PL Capital cuts Nifty target to 26,449, lists 16 high conviction stock picksAmidst global market turmoil from the Iran-US war and El Nino, PL Capital lowered its Nifty 50 target to 26,449. The brokerage anticipates ...
- Stocks in news: Emcure Pharma, Dixon Technologies, Ajanta Pharma, Godrej Properties, VedantaIndian markets experienced a volatile session, closing higher amidst mixed signals. Bulls are defending the 23,000 level in Nifty, but unce...
- Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MFA promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya B...
- More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Ahead of Market: 10 things that will decide stock market action on WednesdayDomestic equities closed marginally lower due to weakness in financial and consumer shares, despite gains in IT stocks. Analysts suggest th...
- Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
- USFDA issues Form-483 with 5 observations to Ajanta Pharma's Paithan facilityAjanta Pharma said the US FDA has issued Form-483 with five observations after inspecting its Paithan manufacturing facility in Maharashtra...
- Buy Ajanta Pharma, target price Rs 2500: Motilal Oswal SecuritiesAjanta Pharma key Products/Revenue Segments include Pharmaceutical Products, Export Incentives and Other Operating Revenue for the year end...
- Sell Ajanta Pharma, target Rs 970: Dr CK NarayanSell Ajanta Pharma Ltd. at a price target of Rs 970.0 and a stop loss at Rs 995 from the entry point.
- Sell Ajanta Pharma, target Rs 1,285: Dharmesh ShahSell Ajanta Pharma Ltd. at a price target of Rs 1285.0 and a stop loss at Rs 1380 from entry point.
- Buy Ajanta Pharma, target Rs 1,300: Kunal BothraBuy Ajanta Pharma at a price target of Rs 1,300 and a stop loss at Rs 1,220 from entry point.
- Ajanta Pharma gets USFDA nod for Parkinson's disease tabletIn a BSE filing, Ajanta Pharma said it has recieved "final approval for Entacapone tablets from US FDA. It is a bioequivalent generic versi...
- Ajanta Pharma Q1 net profit falls 21% to Rs 95 croreThe company had posted a net profit of Rs 119.55 crore for the corresponding period of the previous fiscal.
- Ajanta Pharma launches generic asthma treatment tablets in USAjanta Pharma has launched its generic Montelukast Sodium tablets used for treatment of asthma and seasonal allergies in the American marke...
- Stock Buzz: See another 5-10% appreciation in Ajanta PharmaAjanta Pharma plans have been approved by some important FDA authorities. They have a huge capacity expansion, which is on in Gujarat.
- Stock Buzz: Ajanta Pharma set to benefit from the US upsideIt has been a dream year for Ajanta Pharma but this dream year got over two months ago when Ajanta Pharma hit a new life high of about Rs 1...
- Dabur India eyes Ajanta Pharma's 30-Plus brandThe deal is expected this week and will be under 50 crore, one of the officials said, requesting anonymity.
Load More
